8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 1, 2011

Shire plc

________________________________________________________________________________

(Exact name of registrant as specified in its charter)

Jersey, Channel Islands

________________________________________________________________________________

(State or other jurisdiction of incorporation)

0-29630                                                  98-0601486

(Commission File Number)                (IRS Employer Identification No.)

5 Riverwalk, Citywest Business Campus, Dublin

24, Republic of Ireland

________________________________________________________________________________

(Address of principal executive offices)                              (Zip code)

Registrant's telephone number, including area code               +353 1 429 7700

________________________________________________________________________________

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.f13e-4(c))

Item 8.01.  Other Events

     Shire plc has issued the press releases attached hereto as Exhibit 99.01, Exhibit 99.02 and Exhibit 99.03 which are incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits

                  (d)  Exhibits.  The following exhibits are filed herewith:

99.01                      Press Release dated March 1, 2011

99.02                      Press Release dated March 1, 2011

99.03                      Press Release dated March 1, 2011

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant  has duly caused  this report to be signed on its behalf by the undersigned hereunto duly authorized.

SHIRE PLC
By:	/s/ A C Russell
	Name:	Angus Russell
	Title:	Chief Executive Officer

Dated: March 1, 2011

EXHIBIT INDEX
Number	Description
99.01 99.02 99.03	Press Release dated March 1, 2011 Press Release dated March 1, 2011 Press Release dated March 1, 2011

EX-99.1

Press Release
www.shire.com

Elections for Interim Dividend in Respect of the Six Months to December 31, 2010

March 1, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced on February 10, 2011 an interim dividend of 10.850 US cents per Ordinary Share payable on April 7, 2011 to shareholders on the register of members at the close of business on March 11, 2011.

Shareholders are reminded that the final date for submission of elections to receive UK sourced dividends via the income access share arrangements is March 11, 2011

In the absence of any such elections, previous elections or deemed elections will remain in force.

Shareholders who do not elect (or have not been deemed to elect) to receive UK sourced dividends through the income access share arrangements are reminded that their dividends will be Irish sourced and subject to Irish dividend withholding tax unless the Company's Registrars are in possession of a valid exemption form by March 11, 2011.  Exemption forms may be submitted by fax to + 44 (0) 1903 854 289.

Enquiries may be addressed to the Company Registrars' Dividend Planning Team on + 44 (0) 1903 854 139.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations Eric Rojas (North America) +1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.2

Press Release
www.shire.com

Total Voting Rights

March 1, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,  in accordance with DTR 5.6.1 of the FSA’s Disclosure and Transparency Rules, notifies the market of the following:

At close of business on February 28, 2011, Shire plc's issued voting share capital consisted of 562,231,558 ordinary shares with a nominal value of 5 pence.  Each ordinary share carries one voting right.  Shire plc does not hold any shares in Treasury.

The above figure (562,231,558) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Shire plc under the FSA's Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

EX-99.3

Press Release
www.shire.com

Director/PDMR Shareholding

March 1, 2011 - Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,announces that on February 28, 2011 the following Persons Discharging Managerial Responsibility (“PDMRs”) were granted awards under the Shire Portfolio Share Plan (the “Plan”).

Awards of Stock Appreciation Rights (“SARs”) under Part A of the Plan

Name of PDMR	Type of Security	No of Ordinary Shares or ADSs	Exercise price
Angus Russell (Chief Executive Officer)*	ADSs	63,015	$83.79
Graham Hetherington (Chief Financial Officer)*	Ordinary Shares	82,873	£17.23
Tatjana May	Ordinary Shares	28,379	£17.23
Michael Cola	ADSs	13,552	$83.79
Sylvie Gregoire	ADSs	13,552	$83.79
Barbara Deptula	ADSs	7,896	$83.79

*Vesting of awards granted to Executive Directors is subject to performance targets

SARs will normally vest after three years, subject to any performance targets having been satisfied.  Vested SARs will be capable of exercise for a period of four years.  No consideration was paid for the grant of the SARs.

Performance Share Awards (“PSA Awards”) under Part B of the Plan

Name of PDMR	Type of Security	No of Ordinary Shares or ADSs	Market value
Angus Russell (Chief Executive Officer)*	ADSs	47,262	$83.79
Graham Hetherington (Chief Financial Officer)*	Ordinary Shares	60,769	£17.23
Tatjana May	Ordinary Shares	20,433	£17.23
Michael Cola	ADSs	9,938	$83.79
Sylvie Gregoire	ADSs	9,938	$83.79
Barbara Deptula	ADSs	5,685	$83.79

*Vesting of awards granted to Executive Directors is subject to performance targets

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

The PSA Awards will normally vest after three years, subject to any performance targets having been satisfied.  Once vested, sufficient ordinary shares or ADSs will be transferred or allotted to the participant within 30 days.  No consideration was paid for the grant of the PSA Awards.

This notification is made to satisfy the Company's obligations under 3.1.4(R)(1)(a) of the Disclosure and Transparency Rules.

Tony Guthrie

Deputy Company Secretary

For further information please contact:

Investor Relations
Eric Rojas	erojas@shire.com	+1 781 482 0999

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.  Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions.  Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights.  Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company’s website: www.shire.com.